MENU
+Compare
ACXP
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$0.82
Change
+$0.06 (+7.89%)
Capitalization
13.9M

ACXP Acurx Pharmaceuticals Forecast, Technical & Fundamental Analysis

Industry Biotechnology
ACXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ACXP with price predictions
Dec 20, 2024

ACXP in -6.99% downward trend, declining for three consecutive days on December 16, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ACXP declined for three days, in of 234 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ACXP entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACXP's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on December 20, 2024. You may want to consider a long position or call options on ACXP as a result. In of 60 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ACXP just turned positive on December 13, 2024. Looking at past instances where ACXP's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ACXP advanced for three days, in of 170 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.230) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). ACXP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (256.215).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ACXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ACXP is expected to report earnings to fall 14.71% to -14 cents per share on March 13

Acurx Pharmaceuticals ACXP Stock Earnings Reports
Q4'24
Est.
$-0.14
Q3'24
Missed
by $0.02
Q2'24
Missed
by $0.09
Q1'24
Missed
by $0.04
Q4'23
Missed
by $0.12
The last earnings report on November 13 showed earnings per share of -17 cents, missing the estimate of -15 cents. With 100.93K shares outstanding, the current market capitalization sits at 13.90M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
259 Liberty Avenue
Phone
+1 917 533-1469
Employees
4
Web
https://www.acurxpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NPWR9.600.54
+5.96%
NET Power
NXTT1.90N/A
N/A
Next Technology Holding
SKT34.34-0.01
-0.03%
Tanger
EXPD111.48-1.26
-1.12%
Expeditors International of Washington
KNDI0.90-0.05
-4.76%
Kandi Technologies Group

ACXP and Stocks

Correlation & Price change

A.I.dvisor tells us that ACXP and ALEC have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACXP and ALEC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACXP
1D Price
Change %
ACXP100%
+8.77%
ALEC - ACXP
29%
Poorly correlated
+4.49%
OTLK - ACXP
29%
Poorly correlated
+3.60%
CVM - ACXP
28%
Poorly correlated
-4.60%
INZY - ACXP
27%
Poorly correlated
+6.41%
TSHA - ACXP
26%
Poorly correlated
N/A
More